ABT vs XERS · P/E 25, rev $44.33B vs rev $175.2M
Abbott Laboratories (ABT) versus Xeris Pharmaceuticals Inc (XERS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. XERS currently screens at market cap $760.7M.
Not investment advice. Open the ABT and XERS stock pages for the full models.
Not investment advice.